Want to see CYRX full AI Analyst Report?
CYRX Stock Chart & Stats
$9.21
$0.06(0.70%)
At close: 4:00 PM EST
$9.21
$0.06(0.70%)
Day’s Range― - ―
52-Week Range$6.69 - $16.89
Previous CloseN/A
Volume42.91K
Average Volume (3M)690.07K
Market Cap
$827.61M
Enterprise Value$284.28
Total Cash (Recent Filing)$403.63M
Total Debt (Recent Filing)$230.49M
Price to Earnings (P/E)11.2
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.43
Shares Outstanding50,402,313
10 Day Avg. Volume860,552
30 Day Avg. Volume690,069
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.17Price Target Upside75.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$194.39M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Upward GuidanceSustained top‑line growth and a raised annual guide signal durable demand across commercial and clinical segments. This expands recurring per‑shipment economics, helps spread fixed costs across higher volumes, and supports a clearer pathway to sustained profitability over ensuing quarters.
Deep Clinical & Commercial FootprintA large, maturing trial base with many Phase III programs and growing commercial therapy support creates structural, recurring demand. As trials convert to commercial launches, shipment volumes and higher‑value service adoption should sustainably lift revenue and reduce customer acquisition costs over time.
Manageable Leverage And Improved ROEModerate leverage and a solid equity base provide financial flexibility for capacity builds and working capital needs. Positive TTM ROE suggests capital is generating returns even as operations scale, lowering refinancing risk and supporting disciplined investment in growth initiatives.
Bears Say
Weak Cash GenerationMaterial negative free cash flow indicates the business is not self‑funding growth and requires external capital for investments. Persistent cash deficits constrain capital allocation, increase refinancing exposure, and raise execution risk if revenue or margin improvements slow.
Operating Profitability Not Yet SustainedContinued negative operating margins mean core operations don't consistently cover operating costs. Reported net income is augmented by non‑operating items, so profitability depends on achieving sustained margin expansion, which remains uncertain while scale and product‑mix variability persist.
Long Ramp Times For New Offerings & FacilitiesLengthy onboarding and staggered facility ramps delay revenue and margin contributions from strategic investments. This elongates payback periods, concentrates operational execution risk, and defers expected benefits into 2027, limiting near‑term improvement in cash flow and profitability.
CryoPort News
CYRX FAQ
What was CryoPort Inc’s price range in the past 12 months?
CryoPort Inc lowest stock price was $6.69 and its highest was $16.89 in the past 12 months.
What is CryoPort Inc’s market cap?
CryoPort Inc’s market cap is $827.61M.
When is CryoPort Inc’s upcoming earnings report date?
CryoPort Inc’s upcoming earnings report date is Aug 06, 2026 which is in 13 days.
How were CryoPort Inc’s earnings last quarter?
CryoPort Inc released its earnings results on May 04, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.216 by -$0.034.
Is CryoPort Inc overvalued?
According to Wall Street analysts CryoPort Inc’s price is currently Undervalued.
Does CryoPort Inc pay dividends?
CryoPort Inc does not currently pay dividends.
What is CryoPort Inc’s EPS estimate?
CryoPort Inc’s EPS estimate is -0.19.
How many shares outstanding does CryoPort Inc have?
CryoPort Inc has 50,402,313 shares outstanding.
What happened to CryoPort Inc’s price movement after its last earnings report?
CryoPort Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.216. Following the earnings report the stock price went up 19.393%.
Which hedge fund is a major shareholder of CryoPort Inc?
Currently, no hedge funds are holding shares in CYRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CryoPort Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.17 (75.53% Upside)
$16.17 (75.53% Upside)
Hedge Fund Trend
Increased
By 432.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.11%
Trailing 12-Months
Company Description
CryoPort Inc
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
CYRX Stock 12 Month Forecast
Average Price Target
$16.17
▲(75.53% Upside)
Technical Analysis
Ownership Overview
3.61% Insiders
17.58% Mutual Funds
3.50% Other Institutional Investors
61.34% Public Companies and
Individual Investors







